Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2024-11-06 Interim / Quarterly Rep…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to September 2024. It contains detailed financial summaries (income statements, cash flow, liquidity), management commentary (CEO's letter), and operational updates on clinical trials and projects. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-06 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2024'. It contains comprehensive financial summaries for the quarter and the period, including net turnover, EBITDA, earnings per share, and cash flow data. It also includes detailed management commentary, project updates, and operational highlights. As it covers a period shorter than a full fiscal year and contains substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. 9M 2024
2024-11-06 English
Medivir meddelar nytt kliniskt studiesamarbets- och supplyavtal med Eisai för att utvärdera fostrox i kombination med lenvatinib vid avancerad levercancer
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing a new clinical study collaboration and supply agreement with Eisai Co., Ltd. for the development of a cancer treatment (fostrox). It details the nature of the partnership, the clinical trial phase, and the strategic rationale. This type of corporate announcement regarding business development, partnerships, and clinical trial progress is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement that does not fit into more specific categories like M&A (which usually implies a takeover or merger of the company itself) or specific financial reports.
2024-11-04 Swedish
Medivir announces new clinical trial collaboration and supply agreement with Eisai to evaluate fostrox in combination with lenvatinib in advanced liver cancer
Regulatory Filings Classification · 97% confidence The document is a press release from Medivir AB announcing a new clinical trial collaboration and supply agreement with Eisai. It details the nature of the partnership, the drug candidate (fostrox), and the clinical trial phase (2b). While it discusses clinical data, it is not a formal audit report, financial report, or investor presentation. It is a corporate announcement regarding a strategic business development/partnership, which falls under the 'Regulatory Filings' (RNS) category as it is a public disclosure required by the EU Market Abuse Regulation.
2024-11-04 English
Medivir erhåller en lånefacilitet om 30 miljoner kronor
Capital/Financing Update Classification · 98% confidence The document announces that Medivir has secured a loan facility of 30 million SEK from Linc AB. It details the terms of the facility (drawdown period, repayment terms) and explains the motivation, which is to ensure sufficient funds to complete ongoing clinical studies (Phase 1b/2a and preparation for Phase 2b). The text explicitly mentions that this information is being made public according to the EU's Market Abuse Regulation ('EU:s marknadsmissbruksförordning'). This type of announcement, detailing a specific financing agreement or capital structure change, aligns best with the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2024-10-24 Swedish
Medivir receives loan facility of SEK 30 million
Capital/Financing Update Classification · 98% confidence The document announces that Medivir AB has secured a loan facility of SEK 30 million from Linc AB. This transaction involves fundraising, financing alternatives (equity financing, partnering deal), and changes to the company's capital structure/liquidity position. This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it describes a specific financing event.
2024-10-24 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.